|
Mar 12
|
3 Promising ASX Penny Stocks With Market Caps Over A$20M
|
|
Mar 10
|
Alterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to Billionaires
|
|
Oct 2
|
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
|
|
Sep 30
|
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
|
|
Jul 24
|
Alterity Therapeutics to Present at MST Financial Webinar
|
|
May 8
|
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
|
|
Feb 6
|
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
|
|
Dec 21
|
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
|
|
Dec 5
|
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
|
|
Dec 4
|
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
|
|
Dec 4
|
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data
|
|
Dec 4
|
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
|
|
Nov 27
|
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
|